Loading
Life sciences · Journal article
The Journal of Clinical Endocrinology & Metabolism · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-BMI MASLD), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between normal-BMI MASLD (nbMASLD) and overweight/obesity-associated MASLD (obMASLD) across racial and ethnic groups. METHODS: We conducted a retrospective, observational study using the TriNetX United States Network. Adults diagnosed with MASLD or metabolic dysfunction-associated steatohepatitis (MASH) from 2005-2025 were classified using ethnicity-informed normal-BMI thresholds: <23 kg/m2 for Asian, <27 kg/m2 for Native Hawaiian and Pacific Islander, and <25 kg/m2 for White/others. Propensity-score matching balanced demographic and clinical covariates. Outcomes were assessed using Kaplan-Meier analyses and Cox proportional hazards models with obMASLD as the reference group. RESULTS: Among 619,171 eligible patients, 51,940 matched pairs were identified. Nb-BMI MASLD was associated with higher all-cause mortality across grouped ethnic groups, with survival of 77.49% versus 83.93% in obMASLD (HR 1.735, CI 1.653-1.822). Ethnicity-specific risks included higher myocardial infarction risk in White and Black patients, higher stroke risk in White patients, higher ESRD risk in Black patients, and increased cancers (colorectal, pancreatic and multiple myeloma) among White patients. Incretin-based therapy (IBT) use was markedly lower in nbMASLD but was associated with improved survival. CONCLUSIONS: Patients with nbMASLD demonstrated an increased mortality and ethnicity-specific clinical complications than obMASLD despite a more favorable metabolic profile. These findings demonstrate a potential treatment gap for nbMASLD patients and the shortcomings of BMI-based strategies to risk-stratify MASLD patients.